Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Presentation of KidneyIntelX™ Health Economics Data

March 27, 2020
Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that further to  RNS Reach 2937H on 24 March 2020,  Boston Healthcare Associates has presented data on  KidneyIntelX™, the Company’s AI-enabled in

Podium Presentation and Publication for Health Economics Data

March 24, 2020
Presentation   titled:  Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression Oral presentation accepted for  Late Breaking session  of the National Kidney Foundation Spring Clinical Meeting Accompanying

RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression"

March 24, 2020
Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease   NEW YORK, March 24, 2020 /PRNewswire/ --  Renalytix AI plc (LSE: RENX),  the AIM-traded developer of

Half-year Report

March 3, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces its unaudited interim results for the six months ended 31 December 2019, a period of considerable progress in advancing

Investor briefing

February 26, 2020
Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020. Investor briefing A briefing open to all investors will take

CEO speaking at Cowen 40th Annual Health Care Conference

February 25, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference, which runs from the 1-4 March 2020, hosted at Boston Marriott Copley

New commercial testing facility opens in Utah

January 8, 2020
Download  full announcement Utah issues CLIA Certificate of Registration to allow patient testing New laboratory enables five-fold test volume increase to support 2020 commercial goals Renalytix AI plc (LSE: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney

CMS Pricing Determination becomes effective

January 3, 2020
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that that the national price for KidneyIntelX™ set by the Centers for Medicare and Medicaid Services ("CMS") became effective as of 1 January 2020.

Medicare sets US national price for KidneyIntelX™

December 3, 2019
Download  full announcement US National pricing of $950 effective as of January 1 st , 2020 Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that that the Centers for Medicare and Medicaid Services (“CMS”) has released
Displaying 51 - 60 of 128